ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials
2024-01-03
免疫疗法临床1期
SAN DIEGO, Jan. 3, 2024 /PRNewswire/ -- ChemDiv Inc, a leading provider of drug discovery platforms and development solutions, celebrates a significant milestone in collaboration with Orionis Biosciences: the commencement of Phase I clinical trials for ORB-011, a cutting-edge attenuated, cis-targeted interferon immunotherapy compound.
ORB-011, a pioneering clinical candidate emerging from Orionis' innovative A-Kine® platform, is the culmination of rigorous research and development efforts facilitated by ChemDiv's robust covalent and bifunctional chem-bio arsenal. Engineered to exhibit highly selective, targeted activation of tumor-antigen-presenting cDC1 dendritic cells, ORB-011 leverages ChemDiv's expertise in warheads to optimize interferon's therapeutic potential while mitigating broad systemic activity and associated toxicities characteristic of traditional cytokine therapies.
"We take immense pride in our support of Orionis Biosciences' discovery and development, which has culminated in the advancement of ORB-011 into clinical trials," said ChemDiv's CEO, Bill Farley. "This marks a significant step in harnessing intrinsic immunobiology pharmacologically, and we are excited about the potential impact it may have on revolutionizing cancer therapeutics."
The initiation of Phase I clinical trials for ORB-011 is a significant milestone, underscoring the transformative potential of ChemDiv and Orionis Biosciences synergistic research, pushing the boundaries of collaborative drug discovery to improve patient outcomes in the fight against cancer.
About ChemDiv Inc:
For more information about ChemDiv visit www.chemdiv.com.
For media inquiries, please contact:
Bill Farley
CEO of ChemDiv
[email protected]
SOURCE ChemDiv
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。